Glenmark Pharmaceuticals S.A., a subsidiary of Glenmark Pharmaceuticals India (GPL) and Forest Laboratories, Inc have announced that the top-line results from a phase IIb dose range finding study of Oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD) failed to generate positive results and they are taking further action.
The details can be read here.
No comments:
Post a Comment